David Einhorn's TEVA Position Overview
David Einhorn (via Dme Capital Management, Lp) currently holds 3.8M shares of Teva Pharmaceutical Industries Limited (TEVA) worth $76.33 M, representing 3.00% of the portfolio. First purchased in 2023-Q4, this short-term holding has been held for 8 quarters.
Based on 13F filings, David Einhorn has maintained this position in TEVA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 3.2M shares.
Analysis based on 13F filings available since 2013 Q2
David Einhorn's Teva Pharmaceutical Industries Limited (TEVA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Teva Pharmaceutical Industries Limited (TEVA) Trades by David Einhorn
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2023 | +268,470 | New Buy | 268,470 | $10.44 |
| Q1 2024 | +324,851 | Add 0.00% | 324,850 | $14.11 |
| Q4 2024 | +143,700 | Add 44.24% | 468,550 | $22.04 |
| Q1 2025 | +99,650 | Add 21.27% | 568,200 | $15.37 |
| Q2 2025 | +3.21 M | Add 565.04% | 3.78 M | $16.76 |
David Einhorn's Teva Pharmaceutical Industries Limited Investment FAQs
David Einhorn first purchased Teva Pharmaceutical Industries Limited (TEVA) in Q4 2023, acquiring 268,470 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn has held Teva Pharmaceutical Industries Limited (TEVA) for 8 quarters since Q4 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn's largest addition to Teva Pharmaceutical Industries Limited (TEVA) was in Q2 2025, adding 3,778,777 shares worth $63.33 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, David Einhorn's firm, Dme Capital Management, Lp, owns 3,778,777 shares of Teva Pharmaceutical Industries Limited (TEVA), valued at approximately $76.33 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Teva Pharmaceutical Industries Limited (TEVA) represents approximately 3.00% of David Einhorn's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Einhorn's peak holding in Teva Pharmaceutical Industries Limited (TEVA) was 3,778,777 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.